Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2

Cancer Biotherapy and Radiopharmaceuticals

Volumn 28, Issue 5, 2013, Pages 398-405

  Han, Zheng Xiang ^a,b   Wang, Hong Mei ^b   Jiang, Guan ^b   Du, Xiu Ping ^b   Gao, Xiang Yang ^b   Pei, Dong Sheng ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Bcl 2; lung cancer; Paclitaxel; RNA interference; shRNAs; stathmin

Indexed keywords

MESSENGER RNA; PACLITAXEL; PLASMID VECTOR; PROTEIN BCL 2; SHORT HAIRPIN RNA; STATHMIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CELL GROWTH; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG SENSITIVITY; GENE EXPRESSION; GENE TARGETING; IN VITRO STUDY; LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; STATHMIN; TUMOR CELLS, CULTURED;

EID: 84878819484     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1323     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225.
2. July LV, Beraldi E, So A, et al. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther 2004;3:223.
3. Jones LW, Peddle CJ, Eves ND, et al. Effects of presurgical exercise training on cardiorespiratory fitness among patients undergoing thoracic surgery for malignant lung lesions. Cancer 2007;110:590.
4. Gan PP, Pasquier E, Kavallaris M. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 2007;67:9356.
5. Huisman C, Ferreira CG, Broker LE, et al. Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. Clin Cancer Res 2002;8:596.
6. Alli E, Yang JM, Ford JM, et al. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Mol Pharmacol 2007;71:1233.
7. Belmont LD, Mitchison TJ. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 1996;84:623.
8. van der Vaart B, Akhmanova A, Straube A. Regulation of microtubule dynamic instability. Biochem Soc Trans 2009; 37(Pt 5):1007.
9. Rana S, Maples PB, Senzer N, et al. Stathmin 1: A novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther 2008;8:1461.
10. Jiang G, Liu YQ, Wei ZP, et al. Enhanced anti-tumor activity by the combination of a conditionally replicating adenovirus mediated interleukin-24 and dacarbazine against melanoma cells via induction of apoptosis. Cancer Lett 2010;294:220.
11. Eberle J, Fecker LF, Hossini AM, et al. Apoptosis pathways and oncolytic adenoviral vectors: Promising targets and tools to overcome therapy resistance of malignant melanoma. Exp Dermatol 2008;17:1.
12. Lesinski GB, Raig ET, Guenterberg K, et al. IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis. Cancer Res 2008;68:8351.
13. Aggarwal H, Lubana PS, Jain DK, et al. Estimation of BCL-2 protein in carcinoma of the breast and its clinical correlation in locally advanced breast cancer. J Cancer Res Ther 2007; 3:207.
14. Ngo VN, Davis RE, Lamy L, et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006;441:106.
15. Aagaard L, Rossi JJ. RNAi therapeutics: Principles, prospects and challenges. Adv Drug Deliv Rev 2007;59:75.
16. Rao DD, Vorhies JS, Senzer N, et al. siRNA vs. shRNA: Similarities and differences. Adv Drug Deliv Rev 2009;61:746.
17. Tokumo M, Toyooka S, Kiura K, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005;11:1167.
18. Stewart DJ. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 2010;75:173.
19. Tsai CM, Chiu CH, Chang KT, et al. Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation. J Thorac Oncol 2012;7:1218.
20. Fang L, Min L, Lin Y, et al. Downregulation of stathmin expression is mediated directly by Egr1 and associated with p53 activity in lung cancer cell line A549. Cell Signal 2010;22:166.
21. Singer S, Malz M, Herpel E, et al. Coordinated expression of stathmin family members by far upstream sequence elementbinding protein-1 increases motility in non-small cell lung cancer. Cancer Res 2009;69:2234.
22. Hannon GJ. RNA interference. Nature 2002;418:244.
23. Pennati M, Millo E, Gandellini P, et al. RNA interferencemediated validation of survivin and Apollon/BRUCE as new therapeutic targets for cancer therapy. Curr Top Med Chem 2012;12:69.
24. Gomes-da-Silva LC, Fonseca NA, Moura V, et al. Lipidbased nanoparticles for siRNA delivery in cancer therapy: Paradigms and challenges. Acc Chem Res 2012;45:1163.